

Supplemental Tables for:

Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry
Biomarkers in 312 Breast Cancer Patients

Richard Sheng Poe Huang et al.

Supplemental Table 1. Prevalence of genomic alterations of top 20 genes in HR⁺/HER2⁻, TNBC, and HER2⁺ disease subsets with Bonferroni p-value adjustments for multiple comparisons

Gene	Percent TNBC patients with mutation (n=121)	Percent HR ⁺ /HER2 ⁻ patients with mutation (n=159)	Percent HER2 ⁺ patients with mutation (n=32)	Fisher's Exact Test (adjusted p-value) TNBC and HR ⁺ /HER2 ⁻	Fisher's Exact Test (adjusted p-value) HR ⁺ /HER2 ⁻ and HER2 ⁺	Fisher's Exact Test (adjusted p-value) TNBC and HER2 ⁺
<i>TP53</i>	86.8% (105)	36.5% (58)	71.9% (23)	<0.001	1	1
<i>PIK3CA</i>	18.2% (22)	38.4% (61)	46.9% (15)	0.020	1	0.116
<i>RAD21</i>	31.4% (38)	30.2% (48)	31.3% (10)	1	1	1
<i>MYC</i>	26.4% (32)	19.5% (31)	34.4% (11)	1	1	1
<i>NBN</i>	17.4% (21)	27% (43)	15.6% (5)	1	1	1
<i>WHSC1L1</i>	9.9% (12)	23.9% (38)	15.6% (5)	0.158	1	1
<i>CCND1</i>	8.3% (10)	25.2% (40)	12.5% (4)	0.015	1	1
<i>FGF19</i>	8.3% (10)	23.3% (37)	12.5% (4)	0.065	1	1
<i>FGF3</i>	8.3% (10)	23.3% (37)	12.5% (4)	0.065	1	1
<i>GATA3</i>	10.7% (13)	22.6% (36)	9.4% (3)	0.651	1	1
<i>ZNF703</i>	6.6% (8)	24.5% (39)	9.4% (3)	0.003	0.779	1
<i>FGF4</i>	7.4% (9)	20.8% (33)	15.6% (5)	0.129	1	1
<i>FGFR1</i>	8.3% (10)	20.8% (33)	9.4% (3)	0.257	1	1
<i>CDH1</i>	9.1% (11)	19.5% (31)	3.1% (1)	1	0.195	1
<i>ESR1</i>	3.3% (4)	22% (35)	9.4% (3)	<0.001	1	1
<i>LYN</i>	14% (17)	13.2% (21)	12.5% (4)	1	1	1
<i>DDR2</i>	17.4% (21)	11.3% (18)	6.3% (2)	1	1	1
<i>PTEN</i>	14.9% (18)	15.7% (25)	6.3% (2)	1	1	1
<i>GNAS</i>	14.9% (18)	11.9% (19)	9.4% (3)	1	1	1
<i>RB1</i>	15.7% (19)	10.7% (17)	3.1% (1)	1	1	1

Supplemental Table 2. Prevalence of genomic alterations in the top 20 genes in TNBC/PD-L1⁺ and TNBC/PD-L1⁻ disease subsets

Gene	Percent PDL1 ⁺ patients with mutation (n=52)	Percent PDL1 ⁻ patients with mutation (n=69)	Fisher's Exact Test (p-value)
<i>TP53</i>	90.4% (47)	84.1% (58)	0.419
<i>RAD21</i>	25% (13)	37.7% (26)	0.171
<i>MYC</i>	25% (13)	27.5% (19)	0.836
<i>PIK3CA</i>	15.4% (8)	20.3% (14)	0.635
<i>NBN</i>	9.6% (5)	23.2% (16)	0.057
<i>DDR2</i>	21.2% (11)	14.5% (10)	0.346
<i>RB1</i>	9.6% (5)	20.3% (14)	0.134
<i>GNAS</i>	13.5% (7)	17.4% (12)	0.621
<i>PTEN</i>	15.4% (8)	14.5% (10)	1
<i>MCL1</i>	11.5% (6)	15.9% (11)	0.601
<i>LYN</i>	9.6% (5)	17.4% (12)	0.294
<i>MLL2</i>	11.5% (6)	11.6% (8)	1
<i>NOTCH2</i>	13.5% (7)	10.1% (7)	0.581
<i>GATA3</i>	13.5% (7)	8.7% (6)	0.555
<i>FH</i>	17.3% (9)	5.8% (4)	0.072
<i>PARP1</i>	9.6% (5)	11.6% (8)	0.776
<i>IKBKE</i>	11.5% (6)	10.1% (7)	1
<i>NTRK1</i>	9.6% (5)	11.6% (8)	0.776
<i>BRCA2</i>	9.6% (5)	10.1% (7)	1
<i>WHSC1L1</i>	11.5% (6)	8.7% (6)	0.76